AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03526393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pass training equipment
Description: The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
Study NCT02834117 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: natural cycle
Description: Ovulation is not induced by drugs
Study NCT02834117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moderate ovarian stimulation
Description: Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
Study NCT00999635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
Study NCT00999635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insole
Description: Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
Study NCT03778749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TOF measurements
Description: The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
Study NCT03516708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX chemotherapy
Description: Standard of care
Study NCT03516708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX chemotherapy
Description: Standard of care
Study NCT02122393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Study NCT00003325 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel lymph node mapping
Description: Sentinel lymph node mapping
Study NCT03281486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA formulation Oral Spray
Description: It is an HA formulation of FDA listed ingredients
Study NCT03281486 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation without the active ingredients
Study NCT00468325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-slice computed tomography
Description: Patient receives a CT scan (multi-slice computed tomography) of the heart.
Study NCT00468325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rest-stress Nuclear Myocardial Perfusion Imaging
Description: Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.
Study NCT00468325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-slice Computed Tomography
Description: Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
Study NCT04567225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Glargine
Description: A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion
Study NCT04567225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Late Glargine
Description: A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.
Study NCT04567225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV insulin infusion
Description: Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol
Study NCT04567225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV insulin infusion
Description: Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol
Study NCT04567225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluid and electrolytes replacement
Description: The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
Study NCT03516708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX chemotherapy
Description: Standard of care
Study NCT03292549 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic partial surgery
Description: Robotic partial surgery
Study NCT00292279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil emulsion (Omegaven )
Description: Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
Study NCT00292279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long-chain triglyceride
Description: the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
Study NCT01353443 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optilene® Mesh Elastic
Description: A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
Study NCT00499512 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
Study NCT01223651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two step hyperinsulinaemic glucose clamp study.
Description: Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
Study NCT04399863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ETOILE therapeutic education
Description: ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
Study NCT03462017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR247799
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study NCT03462017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study NCT03462017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Pharmaceutical form:Encapsulated tablet Route of administration: Oral
Study NCT04567225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV fluid and electrolytes replacement
Description: The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
Study NCT00907777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK 1024850A
Description: One dose of vaccine will be injected intramuscularly into the deltoid.
Study NCT00907777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)
Description: One dose of vaccine will be injected intramuscularly into the deltoid.
Study NCT03462017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcholine
Description: Pharmaceutical form:Solution Route of administration: Transdermal
Study NCT03462017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Pharmaceutical form:Solution Route of administration: Transdermal
Study NCT03462017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine
Description: Pharmaceutical form:Solution Route of administration: Transdermal
Study NCT01900171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
Study NCT01900171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains magnesium stearate, silica dental type, anhydrous lactose
Study NCT02402244 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo cytology specimen collection
Study NCT03516708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy
Description: Standard of care
Study NCT03897686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydrous biopolymer with silver ions Argiform
Description: 2 once-weekly intra-articular injections of NOLTREX™ 4.0 ml
Study NCT03897686 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 2 once-weekly intra-articular injections of saline solution 4 ml
Study NCT02402244 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Undergo medical data review
Study NCT00316225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles
Study NCT04779567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 1 gr iv 4 times a day
Study NCT04779567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml saline 0.9% iv 4 times a day
Study NCT04410562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).
Study NCT04410562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
Study NCT02490995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movie
Description: Besides the anesthesist explanations the children will have a movie explanation.
Study NCT03286829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tesomet High dose in fasted condition
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
Study NCT03286829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesomet High dose in fasted condition
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
Study NCT03286829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tesomet Low dose in fasted condition
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
Study NCT03286829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
Study NCT03948763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V941
Description: V941 administered IM, Q3W for 9 3-week cycles
Study NCT02551757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-titrating CPAP
Description: Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
Study NCT02551757 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-CPAP
Description: Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
Study NCT02734940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
Study NCT02734940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unrestricted Fentanyl
Description: No changes to current practices, using unlimited narcotic medications intraoperatively.
Study NCT02734940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
Study NCT02734940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex
Description: This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
Study NCT02734940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duramorph
Description: This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
Study NCT00911820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT00911820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT00911820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT00911820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT03948763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg, IV for 35 3-week cycles
Study NCT05137106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Dry Needling
Description: All participants in this group received an ADN session with an intramuscular insertion of a 25 mm X 0.22 mm acupuncture needle into the infraspinatus muscle. The dry needling was performed with the rapid entry and exit technique.
Study NCT05137106 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry needling
Description: All participants in this group received one session of SDN with a 25 mm X 0.22 mm acupuncture needle over the infraspinatus region. To ensure that the blunt needles did not puncture the skin during the experimental session (and for patient comfort), each needle was individually cut and polished and checked for sharpness against the investigator's fingertip. As a precaution against infection, each patient was treated with a separate dummy needle.
Study NCT03286829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tesomet High dose in fed condition
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
Study NCT01200407 — intervention group
Intervention type: DRUG
Intervention: Amlodipine + Olmesartan medoxomil
Description: start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
Study NCT04488484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serology test follow-up
Description: The enrolled participants will be invited to visit ESS. They will then meet the occupational physician, who wil obtain their free, informed and written consent. The information and consent will be recorded in the personal medical follow-up file.The staff will then complete the self-questionnaire and the ESS physician will provide a prescription for the blood samples to be taken.~In case of positive answers to one or more of the questions in this self-questionnaire, the enrolled participant will be contacted in order to schedule another post-COVID-19 consultation with additional examinations if needed (new COVID PCR, scanner, etc.).
Study NCT03630627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB26
Description: SB26 administered intravenously
Study NCT03630627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously
Study NCT03075540 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Genetic Counseling and Testing YouTube Video
Description: Participants (n=40) will watch a 15-minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a telenovela style format. Participants will complete pre- and post-assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to the patient navigator at their respective sites, who will navigate participants to identified no cost or low cost services
Study NCT00902408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein enriched eggs
Description: 1 year of daily enriched lutein eggs or placebo
Study NCT00902408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lutein enriched eggs
Description: 1 year of daily enriched lutein eggs or placebo
Study NCT01652898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDLA202
Description: Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
Study NCT01652898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONO LDL50
Description: Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
Study NCT01652898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol hydrochloride
Description: Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
Study NCT00023634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH
Description: 100 mcg w/EGFRvIII
Study NCT00023634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMCSF
Description: arm 1: 100 mcg w/EGFRvIII
Study NCT01338766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression using the iO-Flex® system
Description: Decompression using the iO-Flex® system
Study NCT05169749 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control-Service Nurse Group
Description: Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery.
Study NCT05169749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nursing Visiting Group
Description: Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery.
Study NCT04047940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900020
Description: Administered orally
Study NCT04047940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Administered orally
Study NCT04047940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally
Study NCT04047940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Administered orally
Study NCT03867006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days.